Compare WLFC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLFC | VRDN |
|---|---|---|
| Founded | 1985 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 2.7B |
| IPO Year | 1996 | N/A |
| Metric | WLFC | VRDN |
|---|---|---|
| Price | $135.43 | $32.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $39.73 |
| AVG Volume (30 Days) | 45.7K | ★ 1.6M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 17.99 | N/A |
| EPS | ★ 16.70 | N/A |
| Revenue | ★ $674,381,000.00 | $70,789,000.00 |
| Revenue This Year | $16.17 | $26,477.48 |
| Revenue Next Year | $1.26 | $6.23 |
| P/E Ratio | $8.14 | ★ N/A |
| Revenue Growth | 29.58 | ★ 23340.07 |
| 52 Week Low | $114.01 | $9.90 |
| 52 Week High | $229.67 | $33.34 |
| Indicator | WLFC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 60.37 | 65.20 |
| Support Level | $126.56 | $31.11 |
| Resistance Level | $141.71 | $33.29 |
| Average True Range (ATR) | 5.31 | 1.23 |
| MACD | 1.89 | -0.17 |
| Stochastic Oscillator | 74.24 | 69.57 |
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).